BRPI0412441A - método para estabilizar um crioprecipitado de proteìnas plasmáticas para ser submetido a um tratamento térmico de inativação viral - Google Patents
método para estabilizar um crioprecipitado de proteìnas plasmáticas para ser submetido a um tratamento térmico de inativação viralInfo
- Publication number
- BRPI0412441A BRPI0412441A BRPI0412441-3A BRPI0412441A BRPI0412441A BR PI0412441 A BRPI0412441 A BR PI0412441A BR PI0412441 A BRPI0412441 A BR PI0412441A BR PI0412441 A BRPI0412441 A BR PI0412441A
- Authority
- BR
- Brazil
- Prior art keywords
- stabilizing
- proteins
- viral inactivation
- cryoprecipitate
- heat treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/363—Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
"MéTODO PARA ESTABILIZAR UM CRIOPRECIPITADO DE PROTEìNAS PLASMáTICAS PARA SER SUBMETIDO A UM TRATAMENTO TéRMICO DE INATIVAçãO VIRAL". A presente invenção se refere a um método para obtenção de proteínas crioprecipitáveis, compreendendo uma etapa de inativação viral mediante tratamento térmico de um liofilizado dessas proteínas, compreendendo, antes de restituir as proteínas na forma de um liofilizado, uma etapa de adição inicial, a essas proteínas, de uma formulação de estabilização e solubilização contendo uma mistura consistindo em arginina, pelo menos um aminoácido hidrofóbico e citrato de sódio tribásico. A invenção também se refere a um concentrado consistindo em pelo menos uma proteína crioprecipitável contendo a formulação de estabilização e solubilização introduzida de acordo com o método e sendo adequada para uso terapêutico.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0308403A FR2857267B1 (fr) | 2003-07-09 | 2003-07-09 | Formulation stabilisante et solubilisante pour les proteines cryoprecipitables. |
PCT/FR2004/001788 WO2005004901A1 (fr) | 2003-07-09 | 2004-07-08 | Procede de stabilisation d’un cryoprecipite de proteines plasmatiques destine a etre soumis a un traitement thermique d’inactivation virale |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0412441A true BRPI0412441A (pt) | 2006-09-05 |
Family
ID=33522899
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0412441-3A BRPI0412441A (pt) | 2003-07-09 | 2004-07-08 | método para estabilizar um crioprecipitado de proteìnas plasmáticas para ser submetido a um tratamento térmico de inativação viral |
Country Status (13)
Country | Link |
---|---|
US (1) | US7727743B2 (pt) |
EP (1) | EP1648496B1 (pt) |
JP (2) | JP4925822B2 (pt) |
AT (1) | ATE546155T1 (pt) |
AU (1) | AU2004255503B2 (pt) |
BR (1) | BRPI0412441A (pt) |
CA (1) | CA2531419C (pt) |
DK (1) | DK1648496T3 (pt) |
ES (1) | ES2382934T3 (pt) |
FR (1) | FR2857267B1 (pt) |
IL (1) | IL172844A (pt) |
PL (1) | PL1648496T3 (pt) |
WO (1) | WO2005004901A1 (pt) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100624013B1 (ko) * | 2004-06-25 | 2006-09-19 | 주식회사 녹십자홀딩스 | 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제 |
US20060019234A1 (en) * | 2004-07-22 | 2006-01-26 | Shanbrom Technologies, Llc | Modern blood banking employing improved cell preservation composition |
FR2874216B1 (fr) | 2004-08-16 | 2006-11-03 | Lab Francais Du Fractionnement | Procede de preparation d'un concentre de facteur von willebrand (fvw) par voie chromatographique et concentre de fvw susceptible d'etre ainsi obtenu |
FR2894831B1 (fr) * | 2005-12-16 | 2008-02-15 | Lab Francais Du Fractionnement | Colle biologique exempte de thrombine et son utilisation comme medicament. |
ES2264403B1 (es) * | 2006-06-22 | 2007-11-01 | Grifols S.A. | Medio de suspension de hematies. |
CA2692165A1 (en) | 2007-06-25 | 2008-12-31 | Amgen Inc. | Compositions of specific binding agents to hepatocyte growth factor |
US8349367B2 (en) * | 2007-10-12 | 2013-01-08 | Bakaltcheva Irina B | Freeze-dried plasma formats for the trauma care field |
FR2947181B1 (fr) | 2009-06-26 | 2012-05-04 | Lfb Biotechnologies | Composition de facteur vii |
TW201335181A (zh) * | 2012-01-31 | 2013-09-01 | Kieu Hoang | 55種新發現的蛋白質之序列及其應用 |
WO2018007767A1 (fr) * | 2016-07-06 | 2018-01-11 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Fibrinogène liquide stable |
FR3053592B1 (fr) * | 2016-07-06 | 2020-05-29 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Fibrinogene liquide stable |
FR3061020B1 (fr) * | 2016-12-22 | 2019-05-17 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Composition de fibrinogene humain |
WO2019074886A1 (en) | 2017-10-09 | 2019-04-18 | Terumo Bct Biotechnologies, Llc | LYOPHILIZATION CONTAINER AND METHOD OF USE |
US11609043B2 (en) | 2019-03-14 | 2023-03-21 | Terumo Bct Biotechnologies, Llc | Lyophilization container fill fixture, system and method of use |
WO2023119277A1 (en) | 2021-12-21 | 2023-06-29 | Omrix Biopharmaceuticals Ltd. | Highly soluble fibrinogen compositions |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4623717A (en) * | 1980-03-05 | 1986-11-18 | Miles Laboratories, Inc. | Pasteurized therapeutically active protein compositions |
US4456590B2 (en) | 1981-11-02 | 1989-05-30 | Heat treatment of lyphilized blood clotting factor viii concentrate | |
DE3203775A1 (de) * | 1982-02-04 | 1983-08-11 | Behringwerke Ag, 3550 Marburg | Fibrinogenzubereitung, verfahen zu ihrer herstellungund ihre verwendung |
US4470968A (en) * | 1983-01-13 | 1984-09-11 | Miles Laboratories, Inc. | Pasteurized therapeutically active blood coagulation factor concentrates |
CA1260389A (en) | 1984-10-10 | 1989-09-26 | Jay A. Levy | Human plasma, plasma fractions, and compositions thereof substantially free of infectious viruses, bacteria and retroviruses |
JPS6289628A (ja) * | 1985-09-11 | 1987-04-24 | Green Cross Corp:The | 人フイブリノゲン製剤の加熱処理法 |
DE3622642A1 (de) * | 1986-07-05 | 1988-01-14 | Behringwerke Ag | Einkomponenten-gewebekleber sowie verfahren zu seiner herstellung |
JPS6419023A (en) * | 1987-04-21 | 1989-01-23 | Green Cross Corp | Heat treatment of fibrinogen and fibrinogen preparation |
DE3729863A1 (de) * | 1987-09-05 | 1989-03-16 | Boehringer Mannheim Gmbh | Stabilisierte erythropoietin-lyophilisate |
FR2632309B1 (fr) | 1988-06-07 | 1990-08-24 | Lille Transfusion Sanguine | Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus |
AU670793B2 (en) * | 1992-04-30 | 1996-08-01 | Alpha Therapeutic Corporation | Improved solubilization and stabilization of factor VIII complex |
DE4242863A1 (de) * | 1992-12-18 | 1994-06-23 | Boehringer Mannheim Gmbh | Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF |
GB9424732D0 (en) * | 1994-12-08 | 1995-02-08 | Common Services Agency | Heat treated blood plasma proteins |
AUPO871997A0 (en) * | 1997-08-25 | 1997-09-18 | Csl Limited | Dried biologically or therapeutically active preparations |
DK1018345T3 (da) * | 1998-06-26 | 2009-03-23 | Otsuka Pharma Co Ltd | Vandoplöselige, törre sammensætninger |
JP2000247903A (ja) * | 1999-03-01 | 2000-09-12 | Chugai Pharmaceut Co Ltd | 長期安定化製剤 |
JP2001270900A (ja) * | 2000-03-23 | 2001-10-02 | Nihon Pharmaceutical Co Ltd | フィブリノゲンのウイルス不活化法 |
US6623717B2 (en) | 2001-03-28 | 2003-09-23 | Council Of Scientific And Industrial Research | Process for the preparation of LiBF4 |
JP2003055257A (ja) * | 2001-08-10 | 2003-02-26 | Nihon Pharmaceutical Co Ltd | 安定な血液凝固第xiii因子製剤 |
-
2003
- 2003-07-09 FR FR0308403A patent/FR2857267B1/fr not_active Expired - Lifetime
-
2004
- 2004-07-08 DK DK04767620.0T patent/DK1648496T3/da active
- 2004-07-08 PL PL04767620T patent/PL1648496T3/pl unknown
- 2004-07-08 EP EP04767620A patent/EP1648496B1/fr active Active
- 2004-07-08 JP JP2006518297A patent/JP4925822B2/ja not_active Expired - Fee Related
- 2004-07-08 ES ES04767620T patent/ES2382934T3/es active Active
- 2004-07-08 WO PCT/FR2004/001788 patent/WO2005004901A1/fr active Application Filing
- 2004-07-08 US US10/563,620 patent/US7727743B2/en active Active
- 2004-07-08 AU AU2004255503A patent/AU2004255503B2/en not_active Ceased
- 2004-07-08 AT AT04767620T patent/ATE546155T1/de active
- 2004-07-08 CA CA2531419A patent/CA2531419C/fr not_active Expired - Fee Related
- 2004-07-08 BR BRPI0412441-3A patent/BRPI0412441A/pt not_active Application Discontinuation
-
2005
- 2005-12-27 IL IL172844A patent/IL172844A/en not_active IP Right Cessation
-
2011
- 2011-09-26 JP JP2011209633A patent/JP5719266B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
ATE546155T1 (de) | 2012-03-15 |
US20060247426A1 (en) | 2006-11-02 |
JP2012051895A (ja) | 2012-03-15 |
JP4925822B2 (ja) | 2012-05-09 |
CA2531419A1 (fr) | 2005-01-20 |
FR2857267A1 (fr) | 2005-01-14 |
CA2531419C (fr) | 2014-12-23 |
WO2005004901A1 (fr) | 2005-01-20 |
JP5719266B2 (ja) | 2015-05-13 |
AU2004255503B2 (en) | 2010-12-16 |
ES2382934T3 (es) | 2012-06-14 |
EP1648496B1 (fr) | 2012-02-22 |
EP1648496A1 (fr) | 2006-04-26 |
IL172844A0 (en) | 2006-06-11 |
PL1648496T3 (pl) | 2012-07-31 |
AU2004255503A1 (en) | 2005-01-20 |
FR2857267B1 (fr) | 2006-03-10 |
US7727743B2 (en) | 2010-06-01 |
DK1648496T3 (da) | 2012-05-07 |
IL172844A (en) | 2011-11-30 |
JP2007516187A (ja) | 2007-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL172844A0 (en) | Method for stabilizing a cryoprecipitate of plasmatic proteins for being subjected to a viral inactivation thermal treatment | |
EP1408986A4 (en) | PROTEOMIMETIC COMPOUNDS AND CORRESPONDING METHODS | |
DE602004031134D1 (de) | Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa | |
NO20050490L (no) | 2'-C-metyl-3'-O-L-valinester ribofuranosylcytidin for behandling av flaviviridae infeksjoner | |
NO20064584L (no) | Tetrahydropyridoindolderivater | |
CY1109661T1 (el) | 5-cnac ως παραγοντας για χορηγηση απο το στομα τμηματων παραθορμονης | |
DE60219917D1 (de) | Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen | |
EA200300845A1 (ru) | Модифицированные антитела и способы применения | |
EA200401471A1 (ru) | Применение ингибиторов сетр и возможных ингибиторов hmg coa и/или антигипертензивных агентов | |
EA200500169A1 (ru) | Замещенные производные 1,3-дифенилпроп-2-ен-1-она, получение и применение | |
EA200401525A1 (ru) | Способы лечения гепатита (варианты ) | |
EA201892493A1 (ru) | Жидкая композиция нейротоксина, стабилизированная триптофаном или тирозином | |
DE60319083D1 (de) | Pharmazeutische verbindung und methoden zur behandlung von menschlichen karzinomen mittels arginin entzug | |
ES2340842T3 (es) | Anticuerpos anti-apc no neutralizantes. | |
DE60204224D1 (de) | Verwendung bestimmter substituierter pyrrolidone wie z.b. piracetam bei der behandlung von viralen und anderen erkrankungen | |
WO2003063780A3 (en) | Therapeutic composition for treatment of cancer by arginine depletion | |
EA200801731A1 (ru) | Составы и способы лечения тробмоцитемии | |
ATE477810T1 (de) | Stabilisierte albumin-zubereitungen | |
NO20051159L (no) | Preparater og fremgangsmater for behandling av sykdommer som viser feilsammensetting av aggregering av protein | |
NO993407L (no) | Fremstilling av proteinpreparater med nedsatt aggregatinnhold | |
DE602004005821D1 (de) | Enteralpräparat zur vorbeugung gegen bzw. behandlung von sepsis | |
ATE395073T1 (de) | Behandlung von nicht-alkoholischer steatotischer hepatitis (nash) | |
PL1636261T3 (pl) | Białka trombopoetynowe o ulepszonych właściwościach | |
DK1341813T3 (da) | Anvendelse af L-carnitin som stabiliseringsmiddel af proteiner | |
DE60334289D1 (de) | Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |